Abstract 235P
Background
Radiation therapy (RT) is not a standard treatment for ovarian cancer (OC). However, it can be used as an adjunctive therapy to control the local recurrent disease. We aimed to investigate whether OC patients could benefit from RT.
Methods
From 2004 to 2013, the incidence, survival, treatment, and end results data from the SEER were analyzed for cases diagnosed with OC. We examined cause-specific survival (CSS) and overall survival (OS) with 95% confidence intervals (CIs) to estimate the effect of RT from multivariate Cox regression analysis. Performed propensity score matching (PSM) method was used for OC patients who received radiotherapy versus those who did not.
Results
A total of 11140 cases were enrolled for analysis. The aggregated HR of univariate survival analysis suggested that radiotherapy had unfavorable effects on overall survival (HR 1.315, 95% CI 0.994–1.739, P = 0.055) and cancer-specific survival (HR 1.732, 95% CI 1.285–2.334, P < 0.001), but there is no significant difference in multivariate analysis (OS HR 1.315, 95% CI 0.994–1.739, P = 0.055; CSS HR 1.222, 95% CI 0.905–1.651, P = 0.191). After PSM by 1:4, 655 patients were included. Both of the effect of radiotherapy in overall survival (HR 1.341, 95% CI 0.977–1.84, P = 0.070) and cancer-specific survival (HR 1.309, 95% CI 0.931–1.838, P = 0.121) were not significant ever in univariate analysis. Multivariate analysis also found the same results (OS HR 1.232, 95% CI 0.894–1.699, P = 0.202; CSS HR 1.187, 95% CI 0.841–1.674, P = 0.330). Radiotherapy seems to have a reverse effect in regionally spread patients in stage II patients (before PMS HR 3.154, 95% CI 1.709-5.821, p < 0.01; after PMS HR = 3.543, 95% CI 1.603-7.834, p < 0.01) and non-epithelial OC patients (before PMS HR 1.748, 95% CI 1.219-2.507, p = 0.002; after PMS HR = 1.5422, 95% CI 1.021-2.329, p = 0.04).
Conclusions
In OC patients, RT does not have a proven benefit on CSS and OS overall, and it is especially not suitable for early-stage patients and non-epithelial OC patients. However, further confirmation is needed from well-designed and large-scale RCTs in the future to identify its effect in certain types of epithelial OC patients after the developed techniques.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract